Food/Recall·openFDA/food

El Ruisenor De Mexico, Inc. — Class II: Milk Chocolate Covered Raisins; packaged in 1lb, 5lb, 20lb clear plastic units. No UPC

MediumPublished Oct 28, 2026· AI-analyzed Nov 2, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

El Ruisenor De Mexico, Inc. has initiated a Class II recall for Milk Chocolate Covered Raisins due to undeclared milk and soy allergens. The affected products were distributed in 1lb, 5lb, and 20lb clear plastic units without a UPC.

Who it affects

This recall affects El Ruisenor De Mexico, Inc., food distributors, and quality assurance teams responsible for bulk-packaged confectionery labeling and allergen control programs.

Why it matters

The classification as a Class II recall indicates that exposure to the undeclared milk and soy may cause temporary or medically reversible adverse health consequences. For regulatory professionals, this highlights a breakdown in the labeling verification process, particularly for products packaged in varied bulk sizes (1lb to 20lb) where standard UPC identifiers may be absent, potentially complicating traceability during a recall.

Practical takeaway

Quality units should verify that all finished product labels undergo a formal reconciliation against the Master Formulation Record to ensure all constituent allergens (specifically milk and soy in chocolate-based products) are clearly disclosed. Check current inventory of bulk-packaged raisins for appropriate allergen labeling.

FDA source material

Class II. Reason: undeclared allergen ingredient (Milk, Soy). Product: Milk Chocolate Covered Raisins; packaged in 1lb, 5lb, 20lb clear plastic units. No UPC. Firm: El Ruisenor De Mexico, Inc. (Vernon CA United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.